Echo Therapeutics has reported positive results from the clinical trial of its Symphony transdermal continuous glucose monitoring (tCGM) system in elective cardiac surgery patients.

The Symphony tCGM system is a non-invasive, wireless tCGM system for diabetic patients and for use in hospital critical care units.

The study conducted at Tufts Medical Center, US, enrolled 15 adult patients to evaluate the performance of the Symphony tCGM system using the continuous glucose-error grid analysis (CG-EGA) and mean absolute relative difference (MARD) tools.

In the trial, reference blood samples were taken from arterial line catheters at 30-minute intervals and measured on a YSI 2300 STAT Plus glucose analyser and at the end of the study period, the test skin sites were inspected for redness or other undesirable effects.

"Symphony successfully and continuously monitored glucose levels with a MARD or error rate of 12.3%."

The data demonstrated that Symphony successfully and continuously monitored glucose levels in the cardiothoracic surgical intensive care unit, with a MARD or error rate of 12.3%.

Stanley Nasraway, director of Tufts Medical Center Surgical Intensive Care Units and principal investigator of the Tufts study, said Symphony’s accuracy in the study suggested that it is within the expected recommendation that accuracy for intermittent blood glucose measurements in critically ill patients should be less than 12.5% error.

"Echo’s study has produced compelling clinical evidence that this continuous technology can be used for safely sustaining glucose levels within a target range in acutely ill patients," Nasraway added.

"Given the ease of use of this system and the potential cost-savings to hospitals, it is likely that Symphony would transition with critically ill patients from the intensive care units to the hospital general floors where better glucose control through technology-assistance is desperately needed in a setting of fewer nursing resources."